

```
PLEASE ENTER HOST PORT ID:
PLEASE ENTER HOST PORT ID:x
LOGINID:d186tmc
PASSWORD: .
TERMINAL (ENTER 1, 2, 3, 4, OR ?):□3
```

Welcome to MESSENGER (APS Text) at USPTO

The USPTO production files are current through:

MARCH 16,1999 for U.S. Patent Text Data.

MARCH 16,1999 for U.S. Current Classification Data.

MARCH 16,1999 for U.S. Patent Image Data.

AFTER PRODUCTION HOURS (AT 10:00 P.M.) ON WEDNESDAY, 01/27/99,
SEVERAL PTONET DEVICES WILL BE RECONFIGURED TO ENHANCE
NETWORK OPERATIONS. USERS OF PATENT EXAMINER SEARCH TOOLS
MUST RE-BOOT THEIR INDIVIDUAL DESKTOP WORKSTATIONS AT THE
START OF THE BUSINESS DAY ON THURSDAY, 01/28/99 TO INSURE
THAT NECESSARY FILES ON THEIR WORKSTATION GET UPDATED. THIS
WILL ENSURE IMMEDIATE AND ACCURATE ACCESS TO ALL OF THE
PATENT EXAMINER SEARCH TOOLS. THANK YOU FOR YOUR COOPERATION

* PLEASE USE 305-9000 FOR NEW TELEPHONE NUMBER *

More U.S. patent data is now available on APS. The new
USOCR file contains patents issued in 1970, plus some
patents that were missing from the USPAT file. See the
Patents News Folder under the Public Folders in e-mail for
more information on using the new file. Thank you.

DISCLAIMER:
Neither the United States Government, nor any agency
thereof, nor any of their contractors, subcontractors or
employees make any warranty, expressed or implied,
including any warranty of marketability of fitness for a
particular purpose; nor assumes any legal liability or
responsibility for any party's use, or the results of
such, of the data.

Help Desk --> 703-305-9000

The Help Desk is staffed for APS support 7 days/week.
Monday through Friday: 6:30am - 9:00pm
Saturday, Sunday, Holidays: 8:30am - 5:00 pm

The Help Desk staff at this number will handle all APS
related questions.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>><<<<<<<<<<<<<<<<<<<

The APS is available:
6:30am - 9:00pm Monday through Friday

* 7:30am - 5:00pm Saturday, Sunday, Holidays *

* APS is unavailable Thanksgiving Day, Christmas Day, *

* and New Year's Day. *

* * * * *

FILE 'USPAT' ENTERED AT 13:15:26 ON 16 MAR 1999

* * * * *

* W E L C O M E T O T H E *

* U . S . P A T E N T T E X T F I L E *

* * * * *

=> s B7/clm and tumor?/clm

167 B7/CLM

3593 TUMOR?/CLM

L1 6 B7/CLM AND TUMOR?/CLM

=> t 11 1-6

1. 5,861,310, Jan. 19, 1999, Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor; Gordon J. Freeman, et al., 435/325; 424/93.2, 277.1; 435/375 [IMAGE AVAILABLE]
2. 5,858,776, Jan. 12, 1999, Tumor cells with increased immunogenicity and uses therefor; Suzanne Ostrand-Rosenberg, et al., 435/325; 424/93.21; 435/69.1, 320.1, 354, 366, 375 [IMAGE AVAILABLE]
3. 5,833,975, Nov. 10, 1998, Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence; Enzo Paoletti, et al., 424/93.2; 435/69.3, 69.5, 69.51, 69.52, 320.1, 456 [IMAGE AVAILABLE]
4. 5,733,572, Mar. 31, 1998, Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles; Evan C. Unger, et al., 424/450, 1.21, 9.321, 9.4, 489; 436/829 [IMAGE AVAILABLE]
5. 4,886,655, Dec. 12, 1989, Method of detecting infection or immunity in ruminants; John F. T. Griffin, 435/4, 7.24, 7.92, 13, 29; 436/501 [IMAGE AVAILABLE]
6. 4,672,980, Jun. 16, 1987, System and method for creating hyperthermia in tissue; Paul F. Turner, 607/154; 219/696, 704 [IMAGE AVAILABLE]

=> t 1-2 fro clm

US PAT NO:	5,861,310 [IMAGE AVAILABLE]	L1: 1 of 6
DATE ISSUED:	Jan. 19, 1999	
TITLE:	Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor	
INVENTOR:	Gordon J. Freeman, Brookline, MA Lee M. Nadler, Newton, MA Gary S. Gray, Brookline, MA	
ASSIGNEE:	Dana-Farber Cancer Institute, Boston, MA (U.S. corp.)	
APPL-NO:	08/456,104	
DATE FILED:	May 30, 1995	
REL-US-DATA:	Continuation-in-part of Ser. No. 147,773, Nov. 3, 1993, abandoned.	
INT-CL:	[6] C12N 5/00; C12N 5/10; C12N 5/08	
US-CL-ISSUED:	435/325, 375; 424/277.1, 93.2	
US-CL-CURRENT:	435/325; 424/93.2, 277.1; 435/375	
SEARCH-FLD:	435/172.3, 240.2, 375, 325; 424/277.1, 93.2	
REF-CITED:		

U.S. PATENT DOCUMENTS

5,116,964	5/1992	Capon et al.	536/27
5,434,131	7/1995	Linsley et al.	514/2

OTHER PUBLICATIONS

- Freeman, G., et al., "B7, a new Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells," *The Journal of Immunology*, vol. 143, No. 8, 2714-2722 (1989).
- Freeman, G., et al., "Cloning of B7-2; A CTLA-4 Counter-Receptor that Costimulates Human T Cell Proliferation," *Science*, vol. 262, 909-911 (1993).
- Freeman, G., et al., "Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7," *J. Exp. Med.*, vol. 174, 625-631 (1991).
- Galvin, F., et al., "Murine B7 Antigen Provides a Sufficient Costimulatory Signal for Antigen-specific and MHC-restricted T Cell Activation," *The Journal of Immunology*, vol. 149, No. 12, 3802-3808 (1992).
- Gimmi, C., et al., "B-cell Surface Antigen B7 Provides a Costimulatory Signal That Induces T Cells to Proliferate and Secrete Interleukin 2," *Proc. Natl. Acad. Sci. USA*, vol. 88, 6575-6579 (1991).
- Gimmi, C., et al., "Human T-cell Clonal Anergy is Induced by Antigen Presentation in the Absence of B7 Costimulation," *Proc. Natl. Acad. Sci. USA*, vol. 90, 6586-6590 (1993).
- Harding, F. and Allison, J., "CD28-B7 Interactions Allow the Induction of CD8.sup.+ Cytotoxic T Lymphocytes in the Absence of Exogeneous Help," *J. Exp. Med.*, vol. 177, 1791-1796 (1993).
- Harding, F., et al., "CD28-mediated Signalling Co-stimulates Murine T Cells and Prevents Induction of Anergy in T-cell Clones," *Nature*, vol. 356, 607-609 (1992).
- James, R.F.L. et al., "The Effect of Class II Gene Transfection on the Tumorigenicity of the H-2K-negative Mouse Leukaemia Cell Line K36.16," *Immunology*, vol. 72, 213-218 (1991).
- Lenschow, D., et al., "Expression and Functional Significance of an Additional Ligand for CTLA-4," *Proc. Natl. Acad. Sci. USA*, vol. 90, 11054-11058 (1993).
- Linsley, P., et al., "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation," *J. Exp. Med.*, vol. 173, 721-730 (1991).
- Nabavi, N., et al., "Signalling Through the MHC Class II Cytoplasmic Domain is Required for Antigen Presentation and Induces B7 Expression," *Nature*, vol. 360, 266-268 (1992).
- Ostrand-Rosenberg, S., et al., "Abrogation of Tumorigenicity by MHC Class II Antigen Expression Requires the Cytoplasmic Domain of the Class II Molecule," *The Journal of Immunology*, vol. 147, No. 7, 2419-2422 (1991).
- Ostrand-Rosenberg, S., et al., "Costimulation Through Murine B7 Molecule Restores Immunogenicity of Autologous Tumor Cells Expressing Truncated MHC Class II Molecules," *J. Cell. Biochem., Supplement (Abstract HZ 228)*, 71 (1993).
- Ostrand-Rosenberg, S., et al., "Rejection of Mouse Sarcoma Cells After Transfection of MHC Class II Genes," *The Journal of Immunology*, vol. 144, No. 10, 4068-4071 (1990).
- Reiser, H., et al., "Murine B7 Antigen Provides an Efficient Costimulatory Signal for Activation of Murine T Lymphocytes Via the T-cell Receptor/CD3 Complex," *Proc. Natl. Acad. Sci. USA*, vol. 89, 271-275 (1992).
- Baskar, S., et al., "Constitutive Expression of B7 Restores Immunogenicity of Tumor Cells Expressing Truncated Major Histocompatibility Complex Class II Molecules," *Proc. Natl. Acad. Sci. USA*, vol. 90, 5687-5690 (1993).
- Bateman, W.J., et al., "Inducibility of Class II Major Histocompatibility Complex Antigens by Interferon .gamma. is Associated with Reduced Tumorigenicity in C3H Mouse Fibroblasts Transformed by v-Ki-ras," *J. Exp. Med.*, vol. 173, 193-196 (1991).
- Chen, L., et al., "Costimulation of Antitumor Immunity by the B7

by Host Responses to MHC Class I Molecules and is Mediated By CD4-CD8.sup.+ T Lymphocytes That Are Not Lytic for the Tumor" Cellular Immunology 134:480-490.

James, R.F.L. (1991) "The Effect of Class II Gene Transfection on the Tumorigenicity of the H-2K-Negative Mouse Leukaemia Cell Line K36.16" Immunology 172:213-218.

Bateman, W.J. et al. (1991) "Inducibility of Class II Major Histocompatibility Complex Antigens by Interferon .gamma. is Associated with Reduced Tumorigenicity in C3H Mouse Fibroblasts Transformed by v-Ki-ras" J. Exp. Med. 173:193-196.

Freeman, G.J. et al. (1991) "Structure, Expression, and T Cell Costimulatory Activity of the Murine Homologue of the Human B Lymphocyte Activation Antigen B7" J. Exp. Med. 174:625-631.

Linsley, P.S. et al. (1991) "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation" J. Exp. Med. 173:721-730.

Ostrand-Rosenberg, S. et al. (1990) "Rejection Of Mouse Sarcoma Cells After Transfection of MHC Class II Genes" J. Immunology 144:4068-4071.

Fearon, E.R. et al. (1990) "Interleukin-2 Production By Tumor Cells Bypasses T Helper Function in the Generation of An Antitumor Response" Cell 60:397-403.

Schultz, K.R. et al. (1990) "The Role of B Cells for In Vivo T Cell Responses to A Friend Virus-Induced Leukemia" Science 249:921-923.

Freeman, G.J. (1989) "B7, A New Member of the Ig Superfamily With Unique Expression on Activated And Neoplastic B Cells" J. Immunology 143:2714-2722.

Thompson, C.B. et al. (1989) "CD28 Activation Pathway Regulates the Production of Multiple T-Cell-Derived Lymphokines/Cytokines" Proc. Natl. Acad. Sci USA 86:1333-1337.

Freedman, A.S. et al. (1987) "B7, A B Cell-Restricted Antigen That Identifies Preactivated B Cells" J. Immunology 139:3260-3267.

ART-UNIT: 162

PRIM-EXMR: Jasemine C. Chambers

ASST-EXMR: Karen M. Hauda

LEGAL-REP: Amy E. Mandragouras, Megan E. Williams

ABSTRACT:

Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using an agent which induces or increases expression of a T cell costimulatory molecule on the tumor cell surface or by coupling a T cell costimulatory molecule to the tumor cell surface. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor. A method for specifically inducing a CD4.sup.+ T cell response against a tumor and a method for treating a tumor by modification of tumor cells in vivo are disclosed.

18 Claims, 8 Drawing Figures

US PAT NO: 5,858,776 [IMAGE AVAILABLE]

L1: 2 of 6

CLAIMS:

CLMS(1)

We claim:

1. An isolated mammalian **tumor** cell transfected with an exogenous nucleic acid molecule encoding a mammalian **B7** molecule, wherein said molecule is expressed by said **tumor** cell and wherein said **B7** molecule has the ability to costimulate a T cell and the ability to bind

CD28 or CTLA4 ligand.

CLMS(2)

2. The **tumor** cell of claim 1 which expresses an MHC class II molecule.

CLMS(3)

3. The **tumor** cell of claim 1 which expresses an MHC class I molecule.

CLMS(4)

4. The **tumor** cell of claim 1 which normally expresses an MHC class II associated protein, the invariant chain, and wherein expression of the invariant chain is inhibited.

CLMS(5)

5. The **tumor** cell of claim 1 wherein the exogenous nucleic acid is a cDNA in a recombinant expression vector.

CLMS(6)

6. The **tumor** cell of claim 5 further transfected with at least one exogenous nucleic acid molecule encoding:
(a) at least one MHC class II .alpha. chain protein, and
(b) at least one MHC class II chain protein,
wherein said MHC class II .alpha. chain protein(s) and said MHC class II .beta. chain protein(s) is expressed by said **tumor** cell.

CLMS(7)

7. The **tumor** cell of claim 6 which does not express MHC class II molecules prior to transfection of the exogenous nucleic acid molecule encoding said MHC class II .alpha. chain protein(s) and said MHC class II .beta. chain protein(s) into the **tumor** cell.

CLMS(8)

8. The **tumor** cell of claim 1 further transfected with at least one nucleic acid molecule encoding at least one MHC class I .alpha. chain protein wherein said MHC class I protein(s) is expressed by the **tumor** cell.

CLMS(9)

9. The **tumor** cell of claim 8 further transfected with an exogenous nucleic acid molecule encoding a .beta.-2 microglobulin protein, wherein said .beta.2 microglobulin protein is expressed by the **tumor** cell.

CLMS(10)

10. The **tumor** cell of claim 4 wherein expression of the invariant chain is inhibited by transfection of the **tumor** cell with a nucleic acid which is antisense to a regulatory or a coding region of the invariant chain gene.

CLMS(11)

11. The **tumor** cell of claim 1 which is a sarcoma.

CLMS(12)

12. The **tumor** cell of claim 1 which is a lymphoma.

CLMS(13)

13. The **tumor** cell of claim 1 which is selected from a group consisting of a melanoma, a neuroblastoma, a leukemia and a carcinoma.

CLMS(14)

14. An isolated mammalian sarcoma cell transfected with an exogenous nucleic acid molecule encoding a mammalian **B7** molecule wherein said **B7** molecule is expressed in said **tumor** cell and wherein said **B7** molecule has the ability to costimulate a T cell and the ability to bind a CD28 or CTLA4 ligand.

CLMS(15)

15. The sarcoma cell of claim 14 which expresses an MHC class II molecule.

CLMS(16)

16. The sarcoma cell of claim 15 which expresses an MHC class I molecule.

CLMS(17)

17. The **tumor** cell as in any one of claims 1, 2, 5, 13, or 14 wherein the cell is further transfected with an exogenous nucleic acid molecule encoding a cytokine, wherein said cytokine is expressed in said **tumor** cell.

CLMS(18)

18. A composition comprising an amount of the **tumor** cells of any of claims 1, 2, 5, 6, 12, 13, or

=> s cd28/clm or cd(w)28/clm

25 CD28/CLM
49412 CD
149107 28/CLM
1 CD(W)28/CLM
L2 26 CD28/CLM OR CD(W)28/CLM

=> s l2 and tumor?

26324 TUMOR?
L3 24 L2 AND TUMOR?

=> s l3 and tumor?/clm

3593 TUMOR?/CLM
L4 6 L3 AND TUMOR?/CLM

=> t l4 1-6

1. 5,863,538, Jan. 26, 1999, Compositions for targeting the vasculature of solid **tumors**; Philip E. Thorpe, et al., 424/136.1, 138.1, 141.1, 154.1, 155.1, 172.1, 173.1, 174.1, 181.1; 530/387.3, 387.7, 388.22 [IMAGE AVAILABLE]

2. 5,861,310, Jan. 19, 1999, **Tumor** cells modified to express B7-2 with increased immunogenicity and uses therefor; Gordon J. Freeman, et al., 435/325; 424/93.2, 277.1; 435/375 [IMAGE AVAILABLE]

3. 5,858,776, Jan. 12, 1999, **Tumor** cells with increased immunogenicity and uses therefor; Suzanne Ostrand-Rosenberg, et al., 435/325; 424/93.21; 435/69.1, 320.1, 354, 366, 375 [IMAGE AVAILABLE]
4. 5,776,427, Jul. 7, 1998, Methods for targeting the vasculature of solid **tumors**; Philip E. Thorpe, et al., 424/1.49, 93.21, 138.1, 143.1, 145.1, 178.1, 179.1, 181.1, 183.1; 530/387.2, 388.2, 388.73, 391.7 [IMAGE AVAILABLE]
5. 5,750,105, May 12, 1998, Recombinant antibodies for human therapy; Roland A. Newman, et al., 424/133.1, 137.1, 138.1, 177.1; 530/387.3 [IMAGE AVAILABLE]
6. 5,712,149, Jan. 27, 1998, Chimeric receptor molecules for delivery of co-stimulatory signals; Margo R. Roberts, 435/252.3, 69.7, 320.1; 530/350; 536/23.4 [IMAGE AVAILABLE]

=> logoff hold

SESSION WILL BE HELD FOR 30 MINUTES
U.S. Patent & Trademark Office SESSION SUSPENDED AT 13:19:45 ON 16 MAR 199

- Counterreceptor for the T Lymphocyte Molecules CD28 and CTLA-4," Cell, vol. 71, 1093-1102 (1992).
- Clements, V., et al., "Invariant Chain Alters the Malignant Phenotype of MHC Class II.sup.+ Tumor Cells," The Journal of Immunology, vol. 149, No. 7, 2391-2396 (1992).
- Cole, G. and Ostrand-Rosenberg, S., "Rejection of Allogeneic Tumor is not Determined by Host Responses to MHC Class I Molecules and is Mediated by CD4.sup.- CD8.sup.+ T Lymphocytes that are not Lytic for the Tumor," Cellular Immunology, vol. 134, 480-490 (1991).
- Fearon, E., et al., "Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response," Cell, vol. 60, 397-403 (1990).
- Freedman, A., et al., "B7, a B Cell-Restricted Antigen that Identifies Preactivated B Cells," J. Immunology, vol. 139, 3260-3267 (1987).
- Schultz, K., et al., "The Role of B Cells for in Vivo T Cell Responses to a Friend Virus-Induced Leukemia," Science, vol. 249, 921-923 (1990).
- Tan, P., et al., "Induction of Alloantigen-specific Hyporesponsiveness in Human T Lymphocytes by Blocking Interaction of CD28 with its Natural Ligand B7/BB1," J. Exp. Med., vol. 177, 165-173 (1993).
- Thompson, C., et al., "CD28 Activation Pathway Regulates the Production of Multiple T-cell-derived Lymphokines/cytokines," Proc. Natl. Acad. Sci. USA, vol. 86, 1333-1337 (1989).
- Townsend, S. and Allison, J., "Expression of the T Cell Costimulatory Lignad B7 by a Melanoma Induces Rejection Mediated by Direct Activation of CD8.sup.+ T Cells," J. Cell. Biochem., Supplement, (Abstract NZ 627), 136 (1993).
- Townsend, S. and Allison, J., "Tumor Rejection After Direct Costimulation of CD8.sup.+ T Cells by B7-Transfected Melanoma Cells," Science, vol. 259, 368-270 (1993).
- Van Der Bruggen, P., et al., "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma," Science, vol. 254, 1643-1647 (1991).
- ART-UNIT: 162
- PRIM-EXMR: Jasemine C. Chambers
- ASST-EXMR: Karen M. Hauda
- LEGAL-REP: Amy E. Mandragouras, Megan E. Williams

ABSTRACT:

Tumor cells modified to express one or more T cell costimulatory molecules are disclosed. Preferred costimulatory molecules are B7-2 and B7-3. The tumor cells of the invention can be modified by transfection with nucleic acid encoding B7-2 and/or B7-3, by using an agent which induces or increases expression of B7-2 and/or B7-3 on the tumor cell or by coupling B7-2 and/or B7-3 to the tumor cell. Tumor cells modified to express B7-2 and/or B7-3 can be further modified to express B7. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor. A method for specifically inducing a CD4.sup.+ T cell response against a tumor and a method for treating a tumor by modification of tumor cells in vivo are disclosed.

10 Claims, 9 Drawing Figures

US PAT NO: 5,861,310 [IMAGE AVAILABLE]

L1: 1 of 6

CLAIMS:

CLMS(1)

We claim:

1. An isolated mammalian **tumor** cell transfected with an exogenous nucleic acid molecule encoding a mammalian B7-2 molecule, wherein said B7-2 molecule is expressed in said **tumor** cell and wherein said B7-2

molecule has the ability to costimulate a T cell and the ability to bind a CD28 or CTLA4 ligand.

CLMS(2)

2. The **tumor** cell of claim 1, wherein the exogenous nucleic acid is a cDNA in a recombinant expression vector.

CLMS(3)

3. The **tumor** cell of claim 1, which is a sarcoma.

CLMS(4)

4. The **tumor** cell of claim 1, which is a lymphoma.

CLMS(5)

5. The **tumor** cell of claim 1, which is selected from a group consisting of a melanoma, a neuroblastomas, a leukemia and a carcinoma.

CLMS(6)

6. An isolated mammalian sarcoma cell transfected with an exogenous nucleic acid molecule encoding a mammalian B7-2 molecule, wherein said B7-2 molecule is expressed in said **tumor** cell and wherein said B7 molecule has the ability to costimulate a T cell and the ability to bind a CD28 or CTLA4 ligand.

CLMS(7)

7. A composition comprising an amount of the tumor cells of claim 1 and a physiologically acceptable carrier.

CLMS(8)

8. A composition comprising an amount of the **tumor** cells of claim 6, and a physiologically acceptable carrier.

CLMS(9)

9. The cell of any of claims 1, 2, 3, 4, 5, or 6, wherein the nucleic acid molecule has the nucleotide sequence shown in SEQ ID NO: 1.

CLMS(10)

10. The cell of any of claims 1, 2, 3, 4, 5, or 6, wherein the B7-2 molecule has the amino acid sequence shown in SEQ ID NO: 2.

US PAT NO: 5,858,776 [IMAGE AVAILABLE] L1: 2 of 6
DATE ISSUED: Jan. 12, 1999
TITLE: Tumor cells with increased immunogenicity and uses therefor
INVENTOR: Suzanne Ostrand-Rosenberg, Columbia, MD
Sivasubramanian Baskar, Ellicott City, MD
Laurie H. Glimcher, West Newton, MA
Gordon J. Freeman, Brookline, MA
Lee M. Nadler, Newton, MA
ASSIGNEE: Repligen Corporation, Boston, MA (U.S. corp.)
Dana-Farber Cancer Institute, Boston, MA (U.S. corp.)
President and Fellows of Harvard College, Cambridge, MA (U.S. corp.)
APPL-NO: 08/147,772
DATE FILED: Nov. 3, 1993
INT-CL: [6] C12N 15/09; C12N 5/10; C12N 15/63

US-CL-ISSUED: 435/325, 69.1, 172.3, 320.1, 375, 354, 366
US-CL-CURRENT: 435/325; 424/93.21; 435/69.1, 320.1, 354, 366, 375
SEARCH-FLD: 435/172.3, 69.1, 375, 320.1, 325, 354, 366
REF-CITED:

OTHER PUBLICATIONS

- Ginni et al PNAS 88: 6575, 1991.
Travis Science 259: 310, 1993.
Baskar et al PNAS 90: 5687, 1993.
Chen et al Cell 71: 1093, 1992.
Nabavii et al Nature 360: 266, 1992.
Karl et al EMBO J. 6(6): 1677, 1987.
Clements et al J of Immunology 149(?): 2391, 1992.
Uhlman in Chemical Reviews 90(4): 544, 1990.
Gimmi, C.D. et al. (1993) "Human T-Cell Clonal Anergy is Induced by Antigen Presentation in the Absence of B7 Costimulation" Proc. Natl. Acad. Sci. USA 90:6586-6590.
Harding, F.A. et al. (1993) "CD28-B7 Interactions Allow the Induction of CD8.sup.+ Cytotoxic T Lymphocytes in the Absence of Exogenous Help" J. Exp. Med. 177:1791-1796.
Baskar, S. et al. (1993) "Constitutive Expression of B7 Restores Immunogenicity of Tumor Cells Expressing Truncated Major Histocompatibility Complex Class II Molecules" Proc. Natl. Acad. Sci. USA 90:5687-5690.
Ostrand-Rosenberg, S. et al (1993) "Costimulation Through Murine B7 Molecule Restores Immunogenicity of Autologous Tumor Cells Expressing Truncated MHC Class II Molecules" J. Cell Biochem Supplement (Abstract HZ 228) p. 71.
Townsend, S.E. et al. (1993) "Expression of the T Cell Costimulatory Ligand B7 By A Melanoma Induces Rejection Mediated By Direct Activation of CD8+ T Cells" J. Cell Biochem. Supplement (Abstract NZ 627) p. 136.
Travis, J. (1993) "A Stimulating New Approach to Cancer Treatment" Science 259:310-311.
Townsend, S.E. et al. (1993) "Tumor Rejection After Direct Costimulation of CD8.sup.+ T Cells by B7-Transfected Melanoma Cells" Science 259:368-370.
Tan, P. et al. (1993) "Induction of Alloantigen-Specific Hyporesponsiveness in Human T Lymphocytes by Blocking Interaction of CD28 with Its Natural Ligand B7/BB1" J. Exp. Med. 177:165-173.
Chen, L. et al. (1992) "Costimulation of Antitumor Immunity by the B7 Counterreceptor For the T Lymphocyte Molecules CD28 and CTLA-4" Cell 71:1093-1102.
Galvin, F. et al. (1992) "Murine B7 Antigen Provides A Sufficient Costimulatory Signal For Antigen-Specific and MHC-Restricted T Cell Activation" J. Immunology 149:3802-3808.
Nabavi, N. et al. (1992) "Signalling Through the MHC Class II Cytoplasmic Domain is Required For Antigen Presentation and Induces B7 Expression" Nature 360:266-268.
Clements, V.K. et al. (1992) "Invariant Chain Alters The Malignant Phenotype of MHC Class II.sup.+ Tumor Cells" J. of Immunology 149:2391-2396.
Harding, F.A. et al. (1992) "CD28-Mediated Signalling Co-Stimulates Murine T Cells and Prevents Induction of Anergy in T-Cell Clones" Nature 356:607-609.
Reiser, H. et al. (1992) "Murine B7 Antigen Provides an Efficient Costimulatory Signal For Activation of Murine T Lymphocytes Via the T-Cell Receptor/CD3 Complex" Proc. Natl. Acad. Sci. USA 89:271-275.
van Der Bruggen, P. et al. (1991) "A Gene Encoding An Antigen Recognized By Cytolytic T Lymphocytes On A Human Melanoma" Science 254:1643-1647.
Ostrand-Rosenberg, S. et al. (1991) "Abrogation of Tumorigenicity By MHC Class II Antigen Expression Requires The Cytoplasmic Domain of the Class II Molecule" J. Immunology 147:2419-2422.
Gimmi, C.D. et al. (1991) "B-Cell Surface Antigen B7 Provides A Costimulatory Signal That Induces T Cells To Proliferate and Secrete Interleukin 2" Proc. Natl. Acad. Sci. USA 88:6575-6579.
Cole, G.A. et al. (1991) "Rejection of Allogeneic Tumor Is Not Determined